Access TOC
Download Data
December 2024
The global cancer stem cells market size is calculated at US$ 3.2 in 2024, grew to US$ 3.51 billion in 2025, and is projected to reach around US$ 8.04 billion by 2034. The market is expanding at a CAGR of 9.64% between 2025 and 2034. Stem cell-based therapies are highly useful in providing high-quality treatment, due to which stem cells are being continuously grown and studied to treat various cancers.
Unlock Infinite Advantages: Subscribe to Annual Membership
A tiny minority of tumor cells known as cancer stem cells (CSCs) are distinguished by their capacity for self-renewal and unceasing growth. They preserve tumor heterogeneity and promote tumorigenesis and metastasis. Stem cells have been used for more than 30 years to cure cancer using chemotherapy or radiation therapy, or to restore blood and immune systems that have been harmed by cancer cells. In addition to its application in immuno-reconstitution, stem cells have been shown to aid in tissue regeneration and serve as delivery systems for cancer therapies. Scientific communities are now focused on a broad new field of study and potential future cancer treatment approaches thanks to the emerging idea of "cancer stem cells."
Stem cell therapy and artificial intelligence (AI) are two of the most innovative scientific advancements that have the potential to have a big influence on healthcare. Together, they hold the potential to expedite advances in tailored therapies, regenerative medicine, and the comprehension of complicated illnesses. A new age of medical innovation that has the potential to completely transform healthcare is being ushered in by the convergence of AI and stem cell research. Deep learning research in this field has exploded because recent developments in AI technology have made it possible to automatically recognize biological photos of different stem cells, including CSCs.
Growing Demand for Personalized Medicine
For a number of years, stem cells have been at the center of medical study due to their capacity for self-renewal and differentiation, which has become the biggest driver in the cancer stem cell market. Stem cells' revolutionary significance in personalized medicine includes improving and revealing new uses for stem cells in patient-specific treatment customization. In addition to being revolutionary in their own right, these applications highlight the paradigm shift toward more customized medical care.
The immune rejection challenge needs to be addressed
One side effect of stem cell treatment is immunological rejection which is a significant challenge for the cancer stem cells market. The body may assault foreign stem cells because it perceives them as dangerous, leading to damage and inflammation. Hematopoietic stem cells (HSCs), which are stem cells that develop into blood cells, are more prone to experience this.
Growing investment in cancer research
One of the leading causes of death worldwide and a growing burden is cancer. The goal of the World Cancer Research Fund (WCRF) Network is to eliminate malignancies that may be prevented. Over the past ten years, significant progress has been achieved in preventing and curing cancer thanks to research funding from the National Institutes of Health (NIH) and, more especially, the National Cancer Institute (NCI). A future free of cancer depends on sustained federal support in cancer research, even though AICR has provided more than $110 million for research through a grant program.
By mode of action, the targeted cancerous stem cells (CSCs) segment dominated the cancer stem cells market in 2024. Extensive research is being conducted on CSCs in an effort to better understand their behavior and create effective targeted medicines. A number of treatment approaches have been created to target CSCs in an effort to stop cancer from returning. Combining traditional anticancer medications with medicines that target CSCs may be a viable approach to the treatment and elimination of many cancer types.
By mode of action, the stem cell-based cancer therapy segment is expected to grow at the fastest CAGR in the cancer stem cells market during the forecast period. Stem cell-based therapies are becoming more and more promising in the fight against cancer. Because they can locate and target the foci of primary and metastatic tumors, stem cells can serve as innovative delivery vehicles. Immunotherapy, cancer stem cell-targeted treatment, regenerative medicine, and anticancer drug screening are more uses for stem cells.
By cancer form, the breast cancer segment dominated the cancer stem cells market in 2024. About 30% of all new cancer cases in American women each year are breast cancer. Although the overall risk of dying from the illness has decreased due to advancements in screening and treatment, the number of new cases of breast cancer is still increasing. In the United States, breast cancer is the most prevalent cancer to be diagnosed in women. Breast cancer accounts for almost 30% of all newly diagnosed malignancies in women each year. About 310,720 women had a diagnosis of aggressive breast cancer in 2024.
By cancer form, the lung cancer segment is estimated to achieve the fastest growth rate in the cancer stem cells market during the predicted timeframe. 12 per 100,000), even though Ethiopia has an incidence rate that is 60% lower (40 against 100 per 100,000). With about 2.5 million diagnoses (1 in 8 cancers) and 1.8 million fatalities (1 in 5 deaths), lung cancer is the most often diagnosed cancer and the primary cause of cancer-related deaths in both men and women globally. There is considerable interest in using stem cells to treat lung conditions.
North America dominated the cancer stem cells market in 2024. A robust infrastructure for cancer research, including studies on cancer stem cells, has been made possible by the high incidence of cancer in North America, especially in the United States and Canada. Both nations have highly developed healthcare systems and substantial biotechnology research investments. The U.S. is at the forefront of cancer stem cell research worldwide because of significant government and private investment. The U.S. has seen a large number of patent applications pertaining to advancements in diagnostics and cancer stem cell treatments.
Further advancements in cancer detection, treatment, and survival depend on strong funding from federal organizations like the NIH and NCI. To guarantee that the United States maintains a robust clinical and medical research workforce that is generally reflective of society, support is required for education and training initiatives. Through the growth and variety of clinical studies, the FDA is instrumental in accelerating the availability of safe and efficient cancer treatments. In order to lower the risk of cancer and eradicate cancer inequalities, federal organizations such as the NIH, CDC, AHRQ, and EPA, as well as many of its initiatives, are essential.
For instance,
Asia Pacific is estimated to host the fastest-growing cancer stem cells market during the forecast period because of the rise in cancer cases in the region. The geographical growth of the cancer stem cell market is expected to be driven by the presence of several organizations in the region that focus on stem cell research and development, as well as funding organizations that provide funds to research communities to accelerate their scientific investigations on cancer stem cells in Asian countries. China's large population and high cancer incidence rate are responsible for the country's significant market share of cancer stem cells in 2023. For a number of factors, including the nation's aging population, changing lifestyles, and a burgeoning healthcare system, the Indian market for cancer stem cells had a sizable proportion.
In November 2024, Katy Rezvani, M.D., Ph.D., vice president & head of the Institute for Cell Therapy Discovery & Innovation, said that patients with hematologic tumors have seen significant improvements thanks to cell treatments, yet far too many patients continue to see no benefits. Promoting these potential treatments as alternatives for cancer and other patients is essential to our goal. With these findings, we want to reduce the need for extended hospital stays and related expenses by offering many more patients access to efficient cell treatments that are commercially available.
By Mode of Action
By Cancer Form
By Region
December 2024
December 2024
December 2024
November 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts